J.P. Morgan Private Capital (a venture capital and growth equity investment team within J.P. Morgan Asset Management) announced the final closing of the first Life Sciences Private Capital offering, 270 Life Sciences Private Capital Fund I, led by Chief Investment Officer Stephen Squinto, Ph.D. and Managing Partner Gaurav Gupta, M.D., M.S.E.
This fund closed above the $500 million target, bringing strong support from investors, including institutional allocators, strategic corporate partners, family offices and high net worth individuals across North America, Europe, the Middle East, and Asia, and JPMorgan Chase & Co itself.
This fund invests in private biotechnology companies across a wide range of modalities, therapeutic areas, and geographies. And the fund’s early company formation activities and portfolio investments range across cardiometabolic disease, oncology, immunology, and genetic medicines. And the fund also aims to utilize the scale and resources of J.P. Morgan to add value to portfolio companies.
J.P. Morgan Private Capital offers customized financing solutions for private companies across the capital structure with a focus on venture and growth investing. And the platform’s solutions span the consumer, technology, and life sciences sectors. J.P. Morgan Private Capital has a technology and consumer fund; J.P. Morgan Growth Equity Partners, with $1 billion in aggregate commitments that closed in April 2023. And a biotechnology venture fund; 270 Life Sciences Private Capital Fund I, with over $500 million in aggregate commitments that closed in June 2024.
KEY QUOTES:
“We are pleased to announce the close of our inaugural fund, which was raised in just over a year, almost two times faster than our peers in the past decade. As investors and company builders, we are strongly positioned at J.P. Morgan Private Capital to identify and support highly innovative companies that can shape the future of how patients are treated. Our mission is not only to capitalize companies, but also to utilize our collective experience to guide them towards successful outcomes, and to mentor a new generation of biotechnology founders and executives.”
- Dr. Stephen Squinto, Chief Investment Officer and Managing Partner of J.P. Morgan Life Sciences Private Capital
“We are grateful for the support of our investors, and for the key contributions of our strategic advisors and internal team members, as we announce the close of our inaugural life sciences venture capital fund. As the biotechnology industry enters the next era of scientific discovery, we strive to become a partner of choice for world-class researchers and entrepreneurs.”
- Gaurav Gupta, M.D., M.S.E., Managing Partner of J.P. Morgan Life Sciences Private Capital.
